Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update

Gianluigi Ardissino, Francesca Tel, Martina Sgarbanti, Donata Cresseri, Antenore Giussani, Samantha Griffini, Elena Grovetto, Ilaria Possenti, Michela Perrone, Sara Testa, Fabio Paglialonga, Piergiorgio Messa, Massimo Cugno

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab (ECU), a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule is not yet clear. Methods: Here, we report our experience with ECU maintenance treatment and the interval between subsequent doses being extended based on global classical complement pathway (CCP) activity aimed at <30% for maintaining aHUS into remission. Results: We report on 38 patients with aHUS, 13 children, 21 female, with a median age of 25.0 years (range 0.5–60) at disease onset treated with ECU standard schedule for a median of 2.6 months (range 0.4–24.6). Once stable TMA remission was obtained, the interval between ECU doses was extended based on complement function, with a target CCP activity of <30%. With this approach, 22 patients regularly receive ECU infusion every 28 days and 16 every 21. During a median observation period on ECU, an extended interval of 26.9 months (range 0.8–80.9), with a cumulative observation period of 1,208 months, none of the patients relapsed. Conclusion: Monitoring complement activity allows a safe reduction in the frequency of ECU administration in aHUS while keeping the disease in remission.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalPediatric Nephrology
Volume33
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Thrombotic Microangiopathies
Classical Complement Pathway
Therapeutics
Appointments and Schedules
Observation
Antibodies, Monoclonal, Humanized
Hemolysis
eculizumab
Atypical Hemolytic Uremic Syndrome
Blood Platelets

Keywords

  • aHUS
  • Complement activity
  • Eculizumab
  • Maintenance
  • Remission

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome : an update. / Ardissino, Gianluigi; Tel, Francesca; Sgarbanti, Martina; Cresseri, Donata; Giussani, Antenore; Griffini, Samantha; Grovetto, Elena; Possenti, Ilaria; Perrone, Michela; Testa, Sara; Paglialonga, Fabio; Messa, Piergiorgio; Cugno, Massimo.

In: Pediatric Nephrology, Vol. 33, No. 3, 2018, p. 457-461.

Research output: Contribution to journalArticle

Ardissino, Gianluigi ; Tel, Francesca ; Sgarbanti, Martina ; Cresseri, Donata ; Giussani, Antenore ; Griffini, Samantha ; Grovetto, Elena ; Possenti, Ilaria ; Perrone, Michela ; Testa, Sara ; Paglialonga, Fabio ; Messa, Piergiorgio ; Cugno, Massimo. / Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome : an update. In: Pediatric Nephrology. 2018 ; Vol. 33, No. 3. pp. 457-461.
@article{4dce4d95e8e24ce786f7f7f982d4636d,
title = "Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update",
abstract = "Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab (ECU), a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule is not yet clear. Methods: Here, we report our experience with ECU maintenance treatment and the interval between subsequent doses being extended based on global classical complement pathway (CCP) activity aimed at <30{\%} for maintaining aHUS into remission. Results: We report on 38 patients with aHUS, 13 children, 21 female, with a median age of 25.0 years (range 0.5–60) at disease onset treated with ECU standard schedule for a median of 2.6 months (range 0.4–24.6). Once stable TMA remission was obtained, the interval between ECU doses was extended based on complement function, with a target CCP activity of <30{\%}. With this approach, 22 patients regularly receive ECU infusion every 28 days and 16 every 21. During a median observation period on ECU, an extended interval of 26.9 months (range 0.8–80.9), with a cumulative observation period of 1,208 months, none of the patients relapsed. Conclusion: Monitoring complement activity allows a safe reduction in the frequency of ECU administration in aHUS while keeping the disease in remission.",
keywords = "aHUS, Complement activity, Eculizumab, Maintenance, Remission",
author = "Gianluigi Ardissino and Francesca Tel and Martina Sgarbanti and Donata Cresseri and Antenore Giussani and Samantha Griffini and Elena Grovetto and Ilaria Possenti and Michela Perrone and Sara Testa and Fabio Paglialonga and Piergiorgio Messa and Massimo Cugno",
year = "2018",
doi = "10.1007/s00467-017-3813-2",
language = "English",
volume = "33",
pages = "457--461",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

T2 - an update

AU - Ardissino, Gianluigi

AU - Tel, Francesca

AU - Sgarbanti, Martina

AU - Cresseri, Donata

AU - Giussani, Antenore

AU - Griffini, Samantha

AU - Grovetto, Elena

AU - Possenti, Ilaria

AU - Perrone, Michela

AU - Testa, Sara

AU - Paglialonga, Fabio

AU - Messa, Piergiorgio

AU - Cugno, Massimo

PY - 2018

Y1 - 2018

N2 - Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab (ECU), a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule is not yet clear. Methods: Here, we report our experience with ECU maintenance treatment and the interval between subsequent doses being extended based on global classical complement pathway (CCP) activity aimed at <30% for maintaining aHUS into remission. Results: We report on 38 patients with aHUS, 13 children, 21 female, with a median age of 25.0 years (range 0.5–60) at disease onset treated with ECU standard schedule for a median of 2.6 months (range 0.4–24.6). Once stable TMA remission was obtained, the interval between ECU doses was extended based on complement function, with a target CCP activity of <30%. With this approach, 22 patients regularly receive ECU infusion every 28 days and 16 every 21. During a median observation period on ECU, an extended interval of 26.9 months (range 0.8–80.9), with a cumulative observation period of 1,208 months, none of the patients relapsed. Conclusion: Monitoring complement activity allows a safe reduction in the frequency of ECU administration in aHUS while keeping the disease in remission.

AB - Background: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab (ECU), a humanized antibody that blocks complement activity, has been successfully used in aHUS, but the best treatment schedule is not yet clear. Methods: Here, we report our experience with ECU maintenance treatment and the interval between subsequent doses being extended based on global classical complement pathway (CCP) activity aimed at <30% for maintaining aHUS into remission. Results: We report on 38 patients with aHUS, 13 children, 21 female, with a median age of 25.0 years (range 0.5–60) at disease onset treated with ECU standard schedule for a median of 2.6 months (range 0.4–24.6). Once stable TMA remission was obtained, the interval between ECU doses was extended based on complement function, with a target CCP activity of <30%. With this approach, 22 patients regularly receive ECU infusion every 28 days and 16 every 21. During a median observation period on ECU, an extended interval of 26.9 months (range 0.8–80.9), with a cumulative observation period of 1,208 months, none of the patients relapsed. Conclusion: Monitoring complement activity allows a safe reduction in the frequency of ECU administration in aHUS while keeping the disease in remission.

KW - aHUS

KW - Complement activity

KW - Eculizumab

KW - Maintenance

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=85031760281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031760281&partnerID=8YFLogxK

U2 - 10.1007/s00467-017-3813-2

DO - 10.1007/s00467-017-3813-2

M3 - Article

AN - SCOPUS:85031760281

VL - 33

SP - 457

EP - 461

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -